An Introduction to Rare Cancers
A cancer is typically defined as “rare” when it affects a small number of people compared to more common cancers like those of the breast, lung, or prostate. While any single type of rare cancer may be uncommon, collectively they account for a significant portion of all cancer diagnoses. This category includes a vast and diverse group of malignancies, such as sarcomas, neuroendocrine tumors, certain gynecologic or gastrointestinal cancers, and many others.
The treatment of rare cancers presents a unique set of challenges. Because they are seen infrequently, there is often less scientific data, fewer established treatment protocols, and a smaller number of clinical trials available. This makes it crucial for patients to be managed by a highly specialized medical team with specific expertise in their particular disease. The treatment plan is highly individualized and depends on a precise diagnosis, the cancer’s stage, its molecular characteristics, and the patient’s overall health.
The Critical Role of Specialized, High-Volume Cancer Centers
For anyone with a suspected or diagnosed rare cancer, receiving care at a specialized, high-volume cancer center is paramount. These institutions concentrate the necessary expertise and resources required to manage these complex diseases effectively.
Key advantages of a specialized center include:
- Multidisciplinary Team (MDT): These centers have dedicated MDTs for specific rare cancers. This team brings together surgeons, medical oncologists, radiation oncologists, and other specialists who have extensive experience with that particular disease.
- Expert Pathology: An accurate diagnosis is the cornerstone of all cancer treatment, and this is especially true—and especially challenging—for rare cancers. Expert pathologists at high-volume centers have the experience needed to correctly identify rare tumor subtypes, which is a critical step that dictates the entire treatment plan.
- Advanced Diagnostics: Specialized centers have access to advanced imaging and molecular testing capabilities that are essential for accurately staging rare tumors and identifying potential targets for therapy.
- Access to Clinical Trials: These centers are often the primary sites for clinical trials investigating new treatments for rare cancers, providing patients with access to innovative therapies that may not be available elsewhere.
Diagnostic Challenges in Rare Cancers
The journey for a patient with a rare cancer often begins with a diagnostic challenge. Because general physicians and even general oncologists may see a particular rare cancer only once or twice in their career, misdiagnosis or delays in diagnosis can occur.
The first and most important step is obtaining a high-quality biopsy. This biopsy must be reviewed by a pathologist who has a specific interest and expertise in that type of tumor. In many cases, the tissue sample may be sent for a second opinion to a national or international expert to confirm the diagnosis. This expert review is not a luxury; it is a fundamental part of ensuring the patient starts on the correct treatment path.
Foundational Treatment Modalities
While the specific strategy is highly customized, the treatment for rare cancers is built upon the same foundational modalities used for more common cancers.
- Surgery: For most localized rare cancers that have not spread, surgery is the most important curative treatment. The goal is the complete removal of the tumor with a margin of healthy tissue around it. This should be performed by a surgeon with specific experience operating on that type of tumor and at that anatomical location.
- Radiation Therapy: Radiation uses high-energy beams to destroy cancer cells. It may be used after surgery to reduce the risk of local recurrence, as a primary treatment for tumors in locations where surgery is too risky, or as a palliative tool to relieve symptoms caused by tumors.
- Chemotherapy: The role of traditional chemotherapy varies widely among rare cancers. For some, like certain sarcomas or germ cell tumors, it is a highly effective and essential part of treatment. For others, chemotherapy may have little to no effect.
The Growing Importance of Molecular Profiling
Perhaps the single most important advancement in the management of rare cancers is the use of comprehensive molecular or genomic profiling. This involves testing a sample of the tumor tissue to identify the specific genetic mutations and abnormalities that are driving its growth.
Because there may not be an established treatment protocol for a specific rare cancer, identifying its unique molecular fingerprint can sometimes provide a roadmap for treatment. For example, a rare cancer might be found to have a specific mutation for which a targeted therapy drug already exists (perhaps for a different, more common cancer). This “off-label” use of a drug, based on the tumor’s genetic makeup rather than its location in the body, is an increasingly important strategy. This approach is sometimes referred to as “tumor-agnostic” therapy, where the treatment targets a specific mutation, regardless of the cancer type.
The Role of Clinical Trials
For many patients with rare cancers, participating in a clinical trial represents the best possible treatment option. Because standard, approved therapies may be limited, clinical trials provide access to new and innovative treatments that are under investigation. These trials are essential for advancing the scientific understanding of rare diseases and for developing new standards of care for future patients. A discussion about potential clinical trial options should be a part of the treatment planning process for any patient with a rare cancer, particularly if the disease is advanced or has recurred.
Systemic Therapies for Rare Cancers
When a rare cancer has spread or cannot be treated with local therapies like surgery and radiation, systemic medications are used. The choice of drug is highly dependent on the cancer’s subtype and its molecular profile.
- Targeted Therapy: As mentioned, if a tumor has a specific mutation that can be targeted by a drug, this is often the preferred approach. This includes drugs that target specific gene mutations (like KIT in GIST) or pathways that tumors use to grow, such as those involved in forming new blood vessels (angiogenesis).
- Immunotherapy: Immune checkpoint inhibitors, drugs that help the body’s own immune system fight cancer, have shown effectiveness in some rare cancers, particularly those with a specific genetic feature known as high microsatellite instability (MSI-H) or a high tumor mutational burden (TMB).
- Hormone Therapy: For certain rare tumors that are driven by hormones, such as some types of neuroendocrine tumors or sex cord-stromal tumors of the ovary, hormone-blocking therapies can be an effective treatment.
Supportive Care in Rare Cancer Treatment
Supportive, or palliative, care is a vital component of managing a rare cancer. This area of medicine focuses on managing the symptoms of the cancer and the side effects of treatment, with the goal of maintaining the best possible quality of life for the patient. For rare cancers, this can be particularly important. Patients may be dealing with unusual symptoms related to their specific tumor type or may experience unique side effects from novel therapies being used. A dedicated supportive care team works alongside the oncology team to manage pain, nausea, fatigue, nutritional issues, and the significant psychological stress that comes with a rare diagnosis.
Frequently Asked Questions
1. What makes a cancer “rare”?
A cancer is generally considered rare based on its incidence—the number of new cases diagnosed in a population over a certain period. While definitions can vary slightly between organizations, a rare cancer is often defined as one that affects fewer than 6 per 100,000 people per year.
2. Why is a second opinion on the pathology so important for a rare cancer?
The correct classification of a rare cancer’s specific subtype is a highly specialized skill. General pathologists may not have encountered a particular rare tumor before. An expert pathologist who specializes in that disease area can provide a more accurate and nuanced diagnosis, which is absolutely critical because the diagnosis dictates the entire treatment plan. An incorrect diagnosis can lead to ineffective or inappropriate treatment.
3. What is molecular or genomic profiling?
This is a laboratory process where a sample of a patient’s tumor is analyzed to identify the specific genetic mutations and alterations that are causing it to grow. For a rare cancer where standard treatment options may be limited, finding a specific “targetable” mutation can open up new treatment possibilities with targeted therapy drugs.
4. Why is it important to consider a clinical trial for a rare cancer?
Because there are often fewer established or approved treatments for rare cancers, clinical trials provide patients with access to the very latest and most innovative therapies under investigation. Participating in a trial can represent a patient’s best treatment option while also contributing to the vital research needed to help future patients with the same disease.
5. Does “rare” always mean a worse prognosis?
No, not at all. “Rare” simply refers to how frequently a cancer occurs. Many rare cancers, such as testicular germ cell tumors or low-grade neuroendocrine tumors, are highly curable or can be managed as chronic conditions for many years. The prognosis depends entirely on the specific cancer subtype, its stage at diagnosis, and how it responds to treatment.
6. What is a “tumor-agnostic” therapy?
This is a modern approach to cancer treatment that is based on the genetic makeup of the tumor rather than where in the body it originated. A tumor-agnostic drug is one that is approved to treat any type of solid tumor that has a specific genetic mutation, regardless of whether it is a lung cancer, a colon cancer, or a rare sarcoma.
7. Where can patients find reliable information about rare cancers?
Reliable information can often be found through large national cancer organizations, academic cancer centers, and dedicated patient advocacy groups for specific rare cancers. These advocacy groups are often an excellent resource for finding specialists, learning about ongoing research, and connecting with other patients.
